Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

被引：10
|
作者：
Crews, Kristine R. [1 ]
Caudle, Kelly E. [1 ]
Dunnenberger, Henry M. [2 ]
Sadhasivam, Senthilkumar [3 ,4 ]
Skaar, Todd C. [5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] NorthShore Univ Hlth Syst, Ctr Mol Med, Evanston, IL USA
[3] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA
[5] Indiana Univ Sch Med, Div Clin Pharmacol, Dept Med, Indianapolis, IN 46202 USA
来源：
CLINICAL CHEMISTRY | 2015年 / 61卷 / 05期
关键词：
PHARMACOGENETICS; IMPLEMENTATION;
D O I：
10.1373/clinchem.2014.237412
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [31] Venlafaxine serum levels and CYP2D6 genotype
    Veefkind, AH
    Hafmans, PMJ
    Hoencamp, E
    THERAPEUTIC DRUG MONITORING, 2000, 22 (02) : 202 - 208
  • [32] An overview on the allelic variant of CYP2D6 genotype
    Mathew, Shiju
    AFRICAN JOURNAL OF BIOTECHNOLOGY, 2010, 9 (54): : 9096 - 9102
  • [33] CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION
    BROSEN, K
    NIELSEN, PN
    BRUSGAARD, K
    GRAM, LF
    SKJODT, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 47 (03) : 221 - 225
  • [34] Functional phenotyping of the CYP2D6 probe drug codeine in the horse
    S. R. Gretler
    C. J. Finno
    P. H. Kass
    H. K. Knych
    BMC Veterinary Research, 17
  • [35] Functional phenotyping of the CYP2D6 probe drug codeine in the horse
    Gretler, S. R.
    Finno, C. J.
    Kass, P. H.
    Knych, H. K.
    BMC VETERINARY RESEARCH, 2021, 17 (01)
  • [36] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1356 - 1358
  • [37] Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype
    Mikus, G
    Trausch, B
    Rodewald, C
    Hofmann, U
    Richter, K
    Gramatte, T
    Eichelbaum, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (04) : 459 - 466
  • [38] Codeine abuse liability is modified by CYP2D6 inhibition.
    Romach, MK
    Kathiramalainathan, K
    Kaplan, HL
    Busto, UE
    Tyndale, RF
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI107 - PI107
  • [39] Quantitative assessment of the effect of CYP2D6 genotype on tamoxifen metabolism: A model for CYP2D6 genotype-phenotype studies.
    Borges, S
    Desta, Z
    Jin, Y
    Li, L
    Skaar, TC
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P34 - P34
  • [40] Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?
    Cazet, Lucie
    Bulteau, Samuel
    Evin, Adrien
    Spiers, Andrew
    Caillet, Pascal
    Kuhn, Emmanuelle
    Pivette, Jacques
    Chaslerie, Anicet
    Jolliet, Pascale
    Victorri-Vigneau, Caroline
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (08) : 879 - 886
12345